1 completed, 1 recruiting. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow TargetCancer Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TCF-001 TRACK (Target Rare Cancer Knowledge) Study FoundationOne CDx and FoundationOne Liquid CDx - Rare Cancers, Cholangiocarcinoma | Not applicable | Recruiting | TargetCancer Foundation | 400 | 2020-10-01 | 2026-05-26 |
| Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Dasatinib - Cholangiocarcinoma | Phase 2 | Completed | Massachusetts General Hospital | 8 | 2015-04-01 | 2020-07-31 |
Cholangiocarcinoma (2) · Neoplasms, Unknown Primary (1)
Dasatinib (1)
United States (2)
Bruce Giantonio, MD (1) · Mina Nikanjam, MD (1) · Razelle Kurzrock, M.D. (1) · Shumei Kato, M.D. (1) · Vivek Subbiah, M.D. (1)